Literature DB >> 35732920

[Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials].

Etienne Mathier1, Astrid Heusel1, Mohamed Shelan2.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35732920     DOI： 10.1007/s00066-022-01968-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   4.033


× No keyword cloud information.
  4 in total

1.  Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.

Authors:  Vedang Murthy; Priyamvada Maitre; Sadhana Kannan; Gitanjali Panigrahi; Rahul Krishnatry; Ganesh Bakshi; Gagan Prakash; Mahendra Pal; Santosh Menon; Reena Phurailatpam; Smruti Mokal; Dipika Chaurasiya; Palak Popat; Nilesh Sable; Archi Agarwal; Venkatesh Rangarajan; Amit Joshi; Vanita Noronha; Kumar Prabhash; Umesh Mahantshetty
Journal:  J Clin Oncol       Date:  2021-01-26       Impact factor: 44.544

2.  Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.

Authors:  Linda G W Kerkmeijer; Veerle H Groen; Floris J Pos; Karin Haustermans; Evelyn M Monninkhof; Robert Jan Smeenk; Martina Kunze-Busch; Johannes C J de Boer; Jochem van der Voort van Zijp; Marco van Vulpen; Cédric Draulans; Laura van den Bergh; Sofie Isebaert; Uulke A van der Heide
Journal:  J Clin Oncol       Date:  2021-01-20       Impact factor: 44.544

3.  Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy.

Authors:  Daniel N Cagney; Mary Dunne; Carmel O'Shea; Marie Finn; Emma Noone; Martina Sheehan; Lesley McDonagh; Lydia O'Sullivan; Pierre Thirion; John Armstrong
Journal:  BMC Urol       Date:  2017-08-01       Impact factor: 2.264

4.  Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Authors:  Gerhardt Attard; Laura Murphy; Noel W Clarke; William Cross; Robert J Jones; Christopher C Parker; Silke Gillessen; Adrian Cook; Chris Brawley; Claire L Amos; Nafisah Atako; Cheryl Pugh; Michelle Buckner; Simon Chowdhury; Zafar Malik; J Martin Russell; Clare Gilson; Hannah Rush; Jo Bowen; Anna Lydon; Ian Pedley; Joe M O'Sullivan; Alison Birtle; Joanna Gale; Narayanan Srihari; Carys Thomas; Jacob Tanguay; John Wagstaff; Prantik Das; Emma Gray; Mymoona Alzoueb; Omi Parikh; Angus Robinson; Isabel Syndikus; James Wylie; Anjali Zarkar; George Thalmann; Johann S de Bono; David P Dearnaley; Malcolm D Mason; Duncan Gilbert; Ruth E Langley; Robin Millman; David Matheson; Matthew R Sydes; Louise C Brown; Mahesh K B Parmar; Nicholas D James
Journal:  Lancet       Date:  2021-12-23       Impact factor: 79.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.